ChemoCentryx, Inc. to Hold Third Quarter 2013 Fina

MOUNTAIN VIEW, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI ) announced today that the Company's third quarter 2013 financial results will be released after market close on Thursday, November 7, 2013. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2013, to discuss these results and to answer questions.

To participate by telephone, please dial 877-303-8028 (Domestic) or 760-536-5167 (International). The conference ID number is 95243286. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. Vercirnon (also known as Traficet-EN or CCX282), is a Phase III-ready specific CCR9 inhibitor, for the treatment of inflammatory bowel disease. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. Other clinical programs include CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis; CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, as well as CCX872, a CCR2 inhibitor, and CCX507, an inhibitor of CCR9, both of which are in Phase I clinical testing. ChemoCentryx also has several programs in advanced preclinical development.

CCXI - G

Source: ChemoCentryx, Inc.

ChemoCentryx, Inc. Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer; or Markus J. Cappel, PhD Chief Business Officer (650) 210-2900 Investors Caitlyn Murphy Burns McClellan (212) 213-0006 Media Susan Kinkead Kinkead Communications (415) 751-3611